HC Wainwright Forecasts Immunome FY2025 Earnings

Immunome, Inc. (NASDAQ:IMNM) – HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of Immunome in a research report issued to clients and investors on Thursday, February 12th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($2.37) per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for Immunome’s Q4 2025 earnings at ($0.68) EPS, Q1 2026 earnings at ($0.68) EPS, Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.78) EPS, FY2027 earnings at ($2.20) EPS, FY2028 earnings at ($0.79) EPS, FY2029 earnings at $0.63 EPS and FY2030 earnings at $1.28 EPS.

Other equities research analysts have also issued research reports about the stock. Truist Financial started coverage on shares of Immunome in a research report on Monday, December 1st. They issued a “buy” rating and a $36.00 price objective for the company. Stephens upped their price target on shares of Immunome from $25.00 to $33.00 and gave the stock an “overweight” rating in a research report on Monday, November 17th. Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a research report on Thursday, January 15th. Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Finally, Evercore upped their target price on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $31.75.

Immunome Stock Performance

NASDAQ IMNM opened at $22.16 on Monday. The firm has a market capitalization of $2.44 billion, a price-to-earnings ratio of -7.51 and a beta of 2.32. Immunome has a one year low of $5.15 and a one year high of $27.65. The company’s 50 day moving average price is $22.53 and its 200 day moving average price is $16.63.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in IMNM. Nisa Investment Advisors LLC boosted its holdings in shares of Immunome by 3,513.0% during the third quarter. Nisa Investment Advisors LLC now owns 80,426 shares of the company’s stock valued at $942,000 after acquiring an additional 78,200 shares during the period. Kennedy Capital Management LLC increased its holdings in shares of Immunome by 642.6% in the 2nd quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock worth $1,017,000 after acquiring an additional 94,627 shares during the period. Nan Fung Trinity HK Ltd. lifted its position in Immunome by 7.9% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 592,103 shares of the company’s stock valued at $6,934,000 after purchasing an additional 43,253 shares during the last quarter. Tema Etfs LLC acquired a new position in Immunome during the 2nd quarter valued at about $1,074,000. Finally, Intech Investment Management LLC grew its position in Immunome by 17.8% in the 2nd quarter. Intech Investment Management LLC now owns 40,565 shares of the company’s stock worth $377,000 after purchasing an additional 6,141 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Activity

In other Immunome news, Director Isaac Barchas sold 383,200 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the transaction, the director directly owned 2,031,181 shares of the company’s stock, valued at $44,157,874.94. This represents a 15.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Philip Tsai acquired 10,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were purchased at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the purchase, the insider directly owned 43,300 shares of the company’s stock, valued at $887,217. This represents a 30.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 68,518 shares of company stock worth $1,453,958 over the last ninety days. Corporate insiders own 7.69% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.